Effect of breviscapine injection on clinical parameters in diabetic nephropathy: A meta-analysis of randomized controlled trials

Experimental and Therapeutic Medicine

Volumn 12, Issue 3, 2016, Pages 1383-1397

  Liu, Xiaodan ^a   Yao, Li ^a   Da Sun, ^a   Zhu, Xinwang ^a   Liu, Qiang ^a   Xu, Tianhua ^a   Wang, Lining ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Blood fat; Breviscapine; Diabetic nephropathy; Renal function; Urine protein

Indexed keywords

BREVISCAPINE;

ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETIC NEPHROPATHY; GENETIC HETEROGENEITY; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84980390640     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3483     Document Type: Article

References (65)

1. Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY and He JC: Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63: 2440-2453, 2014.
2. Lai X, Zhang AH, Chen SY, He L, Su CY, Fan MH and Wang T: Outcomes of stage 1-5 chronic kidney disease in Mainland China. Ren Fail 36: 520-525, 2014.
3. Stanton RC: Frontiers in diabetic kidney disease: Introduction. Am J Kidney Dis 63 (2 Suppl 2): S1-S2, 2014.
4. Roscioni SS, Heerspink HJ and de Zeeuw D: The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 10: 77-87, 2014.
5. Zhang RW, Zhang YL, Wang JS, Lin YY and Shang B: Isolation and identification of flavonoids from shortscape fleabane (Erigeron breviscapus). Zhong Cao Yao 19: 199-201, 1988(In Chines).
6. Wang M, Xie C, Cai RL, Li XH, Luo XZ and Qi Y: Studies on antioxidant activities of breviscapine in the cell-free system. Am J Chin Med 36: 1199-1207, 2008.
7. Wang M, Zhang WB, Zhu JH, Fu GS and Zhou BQ: Breviscapine ameliorates cardiac dysfunction and regulates the myocardial Ca(2+)-cycling proteins in streptozotocin-induced diabetic rats. Acta Diabetol 47 (Suppl 1):S209-S218, 2010.
8. Jia JH, Chen KP, Chen SX, Liu KZ, Fan TL and Chen YC: Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol 63: 757-762, 2008.
9. Cao W, Liu W, Wu T, Zhong D and Liu G: Dengzhanhua preparations for acute cerebral infarction. Cochrane Database Syst Rev 4: CD005568, 2008.
10. He M, Xue ZM, Li J and Zhou BQ: Breviscapine inhibits high glucose-induced proliferation and migration of cultured vascular smooth muscle cells of rats via suppressing the ERK1/2 MAPK signaling pathway. Acta Pharmacol Sin 33: 606-614, 2012.
11. Kang SQ and Liu JY: Effect of breviscapine on urinary micro-albumine in patients with diabetes mellitus type 2. Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 458-459, 2003(In Chines).
12. Wei L and Tan J: Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment. Chin J Integr Med 11: 31-33, 2005.
13. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. World Health Organisation. 1999.
14. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 7:1183–1197, 1997.
15. Mogensen CE, Christensen CK and Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl 2): 64-78, 1983.
16. Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ: Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 88:156-175, 2008.
17. Chen XH: Clinical observation of therapy with Breviscapine for diabetic nephropathy. Zhongguo Liao Yang Yi Xue 16: 168-169, 2007(In Chines).
18. Yu JP: Breviscapine valsartan combined treatment of early diabetic nephropathy. Zhonghua Zhong Yi Yao Xue Kan 28: 1337-1338, 2010 (In Chines).
19. Wang XM: Impact of valsartan combined breviscapine trace urinary albumin in diabetic nephropathy and serum C-reactive protein. Lin Chuang He Li Yong Yao Za Zhi 2: 25-26, 2009(In Chines).
20. Huang WY: Observation of therapeutic effects with losartan and breviscapine on early diabetic nephropathy. Zhongguo Xiang Cun Yi Xue 18: 27-28, 2011(In Chines).
21. Shen YF and Dai Z: Clinical observation of therapy with candesartan and breviscapine on diabetic nephropathy. Zhongguo Shi Yong Yi Yao 6: 148-149, 2011 (In Chines).
22. Wu JY, Liang D, Ma ZH and Chen GH: Clinical observation of therapeutic effects with irbesartan and breviscapine on diabetic nephropathy. Guo Ji Yi Yao Wei Sheng Dao Bao 15: 53-55, 2009 (In Chines).
23. Huang WS and Sheng P: Clinical observation of therapy with breviscapine injection on early diabetic nephropathy. Dang Dai Yi Xue 10: 58-59, 2004 (In Chines).
24. Li H: Clinical observation of treatment effects with breviscapine injection and enalapril on 76 patients with diabetic nephropathy. Shi Yong Lin Chuang Yi Yao Za Zhi 10: 85-86, 2006(In Chines).
25. Fang X: Evaluation of therapeutic effects with breviscapine injection and enalapril on early diabetic nephropathy. Dang Dai Yi Xue 17: 131-132, 2011 (In Chines).
26. Qiao FB, Tian Z and He YL: Observation of treatment with breviscapine injection and benazepril on 52 cases with azotemia of diabetic nephropathy. Zhongguo Yao Ye 18: 55-56, 2009(In Chines).
27. Zhong L and Li K: Therapeutic effect of Breviscapine combined with Enalapril on early diabetic nephropathy. Hua Xi Yi Xue 26: 493-495, 2011(In Chines).
28. Liu HB, Liu CHA and Li XN: Observation of therapeutic effects with breviscapin on 68 cases with early diabetic nephropathy. Qingdao Yi Yao Wei Sheng 43: 41-42, 2011 (In Chines).
29. Xu YF and Yu JH: Clinical observation of treatment with breviscapin on 36 cases with diabetic nephropathy. Fu Jian Yi Yao Za Zhi 30: 133-134, 2008(In Chines).
30. Wu JW, Ling JH and Huang XN: Clinical observation of treatment with breviscapin and telmisartan on early diabetic nephropathy. Lin Chuang He Li Yongyao Za Zhi 4: 54-55, 2011 (In Chines).
31. Liu SC, Wen FG and Zhao CY: Clinical observation of treatment with breviscapin and lotensin on urinary protein of early diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 27: 530, 2007(In Chines).
32. Liu SC and Zhao CY: Protective effects of treatment with breviscapin and lotensin on early diabetic nephropathy. Guo Ji Zhong Yi Zhong Yao Za Zhi 29: 246-247, 2007(In Chines).
33. Jiang YF, He LQ and Shen LP: Clinical observation on therapeutic effects of combined use of dengzhanhuasu and losartan in treating early diabetic nephropathy. Liaoning Zhong Yi Xue Yuan Xue Bao 12: 43-45, 2010 (In Chines).
34. Zhang P: Clinical observation on breviscapin combined with cozaar for diabetic nephropathy. Zhongguo Yao Fang 17: 1403-1404, 2006(In Chines).
35. Qiao FB, Li CT, Li LF, Zhang CJ, He QL and Ren LX: Clinical observation of treatment with breviscapine and candesartan on early diabetic nephropathy. Yi Nan Bing Za Zhi 9: 606-608, 2010 (In Chines).
36. Lan HP and Wu FQ: Clinical observation of treatment with breviscapine on diabetic nephropathy. Zhengjiang Lin Chuang Yi Xue 10: 389, 2008(In Chines).
37. Huang J, Wen Z and Feng Y: Clinical observation of treatment with breviscapine on diabetic nephropathy. Zhongguo Bao Jian Ying Yang 9: 3347-3348, 2012(In Chines).
38. Zhai SC: Analysis of treatment with breviscapine on diabetic nephropathy. Shandong Yi Yao 40: 69-70, 2000(In Chines).
39. Wang YX: Clinical observation of therapy with breviscapine injection on diabetic nephropathy. Zhong Wai Yi Liao 30: 126, 2011(In Chines).
40. Qian F: Clinical observation of therapeutic effects with breviscapine injection on 60 patients with diabetic nephropathy. An Mo Yu Kang Fu Yi Xue 2: 91-92, 2011(In Chines).
41. Li J: Observation of therapeutic effects with breviscapine injection and valsartan on early diabetic nephropathy. Zhongguo She Qu Yi Shi 12: 117, 2010(In Chines).
42. Wang W, Xing L, Wang CH and Li JC: Influence of breviscapine injection on hemorrheology and microcirculation of patients with diabetic nephropathy. Zhonghua Zhong Yi Yao Xue Hui 14: 963, 997, 2005(In Chines).
43. Li J, Wu LY and Wang CY: Influence of breviscapine injection to correlated inflammatory cytokines in patients with type 2 early diabetic nephropathy. Zhong Yao Yao Li Yu Lin Chuang 27: 110-112, 2011(In Chines).
44. Zhao S: Observation of therapeutic effects with breviscapin on diabetic microalbuminuria. Guiyang Zhong Yi Xue Yuan Xue Bao 34: 37-38, 2012 (In Chines).
45. Liu YC: Observation of therapeutic effects with breviscapine on diabetic nephropathy. She Qu Zhong Yi Yao 10:76, 2008 (In Chines).
46. Liu DK: Observation of therapeutic effects with breviscapin on hyperviscosity in diabetic nephropathy. Hubei Zhong Yi Za Zhi 25: 13-14, 2003 (In Chines).
47. Yuan CL and Yuan LY: Clinical observation of therapeutic effects with breviscapine on diabetic nephropathy. Shi Yong Tang Niao Bing Za Zhi 2:23, 2005 (In Chines).
48. Guo FH, Lv GY and Fan P: Clinical observation of therapy with valsartan and Dengzhanhuasu for diabetic nephropathy. Zhonghua Quan Ke Yi Xue 6: 895-896, 2008 (In Chines).
49. Huang GN, Chen JY and Zhang MY: Hemorrheology impact of treatment with breviscapine injection on diabetic nephropathy. Xin Zhong Yi 38: 34-35, 2006 (In Chines).
50. Cai HY. Clinical observation of treatment with breviscapin on 30 cases with early diabetic nephropathy. Dang Dai Yi Xue 15: 148, 2009 (In Chines).
51. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 379:2279-2290, 2012.
52. Higgins GC and Coughlan MT: Mitochondrial dysfunction and mitophagy: The beginning and end to diabetic nephropathy? Br J Pharmacol 171: 1917-1942, 2014.
53. Stanton RC: Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 63 (2 Suppl 2): S3-S21, 2014.
54. Badal SS and Danesh FR: New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 63 (2 Suppl 2): S63-S83, 2014.
55. Mima A: Inflammation and oxidative stress in diabetic nephropathy: New insights on its inhibition as new therapeutic targets. J Diabetes Res 2013: 248563, 2013.
56. Xu XX, Zhang W, Zhang P, Qi XM, Wu YG and Shen JJ: Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats. Phytomedicine 20: 820-827, 2013.
57. Qi XM, Wu GZ, Wu YG, Lin H, Shen JJ and Lin SY: Renoprotective effect of breviscapine through suppression of renal macrophage recruitment in streptozotocin-induced diabetic rats. Nephron Exp Nephrol 104: e147-e157, 2006.
58. Zhao Y, Yang QP, Xiao H, Zhao C, Liu H and Song DP: The effect of Erigeron breviscapus on apoptosis and expression of bax, bcl-2 in kidney of diabetic rats. Zhonghua Tang Niao Bing Za Zhi 17: 864-867, 2009(In Chines).
59. Wagener FA, Dekker D, Berden JH, Scharstuhl A and van der Vlag J: The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 14: 1451-1458, 2009.
60. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, et al: The CARI guidelines. Assessment of kidney function in type 2 diabetes. Nephrology (Carlton) 15 (Suppl 1): S146-S161, 2010.
61. Wang SH, Wang L, Zhou Y, Guo YJ, Yuan Y, Li FF, Huang Y and Xia WQ: Prevalence and control of dyslipidaemia among diabetic patients with microalbuminuria in a Chinese hospital. Diab Vasc Dis Res 10: 169-178, 2013.
62. Tomkin GH. Targets for intervention in dyslipidemia in diabetes. Diabetes Care 31 Suppl 2:S241-248, 2008.
63. Stadler K, Goldberg IJ, Susztak K. The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep 15: 40, 2015.
64. Chen HC, Guh JY, Chang JM, Hsieh MC, Shin SJ and Lai YH: Role of lipid control in diabetic nephropathy. Kidney Int Suppl: S60-S62, 2005.
65. Chen SC and Tseng CH: Dyslipidemia, kidney disease and cardiovascular disease in diabetic patients. Rev Diabet Stud 10: 88-100, 2013.